AstraZeneca AZN Stock
AstraZeneca Price Chart
AstraZeneca AZN Financial and Trading Overview
| AstraZeneca stock price | 70.82 USD |
| Previous Close | 72.77 USD |
| Open | 74 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 900 |
| Day's Range | 73.59 - 74.74 USD |
| 52 Week Range | 52.65 - 76.56 USD |
| Volume | 4.45M USD |
| Avg. Volume | 4.14M USD |
| Market Cap | 231.3B USD |
| Beta (5Y Monthly) | 0.194636 |
| PE Ratio (TTM) | 48.141937 |
| EPS (TTM) | 2.49 USD |
| Forward Dividend & Yield | 1.45 (1.99%) |
| Ex-Dividend Date | February 23, 2023 |
| 1y Target Est | 80.25 USD |
AZN Valuation Measures
| Enterprise Value | 1.42T USD |
| Trailing P/E | 48.141937 |
| Forward P/E | 17.47541 |
| PEG Ratio (5 yr expected) | 1.52 |
| Price/Sales (ttm) | 5.276063 |
| Price/Book (mrq) | 38.910892 |
| Enterprise Value/Revenue | 32.359 |
| Enterprise Value/EBITDA | 95.3 |
Trading Information
AstraZeneca Stock Price History
| Beta (5Y Monthly) | 0.194636 |
| 52-Week Change | 22.14% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 76.56 USD |
| 52 Week Low | 52.65 USD |
| 50-Day Moving Average | 73.91 USD |
| 200-Day Moving Average | 66.48 USD |
AZN Share Statistics
| Avg. Volume (3 month) | 4.14M USD |
| Avg. Daily Volume (10-Days) | 5.04M USD |
| Shares Outstanding | 3.1B |
| Float | 18.59B |
| Short Ratio | 1.42 |
| % Held by Insiders | 0.0060% |
| % Held by Institutions | 18.10% |
| Shares Short | 4.88M |
| Short % of Float | N/A |
| Short % of Shares Outstanding | 0.16% |
Dividends & Splits
| Trailing Annual Dividend Rate | 2.9 |
| Trailing Annual Dividend Yield | 3.98% |
| 5 Year Average Dividend Yield | 277.00% |
| Payout Ratio | 0.96029997 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 10.73% |
| Operating Margin (ttm) | 23.09% |
| Gross Margin | 84.30% |
| EBITDA Margin | 33.95% |
Management Effectiveness
| Return on Assets (ttm) | 6.42% |
| Return on Equity (ttm) | 13.05% |
Income Statement
| Revenue (ttm) | 43.84B USD |
| Revenue Per Share (ttm) | 2.35 USD |
| Quarterly Revenue Growth (yoy) | -4.50% |
| Gross Profit (ttm) | 35.73B USD |
| EBITDA | 14.89B USD |
| Net Income Avi to Common (ttm) | 4.7B USD |
| Diluted EPS (ttm) | 1.55 |
| Quarterly Earnings Growth (yoy) | 367.09% |
Balance Sheet
| Total Cash (mrq) | 6.46B USD |
| Total Cash Per Share (mrq) | 0.35 USD |
| Total Debt (mrq) | 32.47B USD |
| Total Debt/Equity (mrq) | 90.68 USD |
| Current Ratio (mrq) | 0.896 |
| Book Value Per Share (mrq) | 1.917715 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 9.71B USD |
| Levered Free Cash Flow (ttm) | 9.69B USD |
Profile of AstraZeneca
| Country | United States |
| State | N/A |
| City | Cambridge |
| Address | 1 Francis Crick Avenue |
| ZIP | CB2 0AA |
| Phone | 44 20 3749 5000 |
| Website | https://www.astrazeneca.com |
| Industry | Drug Manufacturers-General |
| Sector(s) | Healthcare |
| Full Time Employees | 83500 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Q&A For AstraZeneca Stock
What is a current AZN stock price?
AstraZeneca AZN stock price today per share is 70.82 USD.
How to purchase AstraZeneca stock?
You can buy AZN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AstraZeneca?
The stock symbol or ticker of AstraZeneca is AZN.
Which industry does the AstraZeneca company belong to?
The AstraZeneca industry is Drug Manufacturers-General.
How many shares does AstraZeneca have in circulation?
The max supply of AstraZeneca shares is 3.1B.
What is AstraZeneca Price to Earnings Ratio (PE Ratio)?
AstraZeneca PE Ratio is 28.44176700 now.
What was AstraZeneca earnings per share over the trailing 12 months (TTM)?
AstraZeneca EPS is 2.49 USD over the trailing 12 months.
Which sector does the AstraZeneca company belong to?
The AstraZeneca sector is Healthcare.
AstraZeneca AZN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 20611.34 USD — |
+0.94
|
9.27B USD — | 20486.39 USD — | 20645.41 USD — | — - | 9.27B USD — |
| US100 NDX | 22864.91 USD — |
+0.72
|
1.08B USD — | 22733.65 USD — | 22915.33 USD — | — - | 1.08B USD — |
| Nasdaq-100 ESG Net Notional Tot NDXESG24 | 1746.17 EUR 1908.8 USD |
+0.54
|
— — | 1736.61 EUR 1898.35 USD | 1752.58 EUR 1915.81 USD | — - | — — |
| Nasdaq-100 Notional Net Return XNDXNNREUR | 4064.31 EUR 4442.85 USD |
+0.52
|
— — | 4041.9 EUR 4418.35 USD | 4077.4 EUR 4457.15 USD | — - | — — |
| NASDAQ-100 Equal Weighted NDXE | 8403.16 USD — |
+0.18
|
— — | 8351.13 USD — | 8425.38 USD — | — - | — — |
| Nasdaq-100 Micro Index XND | 228.65 USD — |
+0.72
|
— — | 227.34 USD — | 229.15 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| Stlmt ID NASDAQ 100 XQO | 16266.86 USD — |
-0.45
|
— — | 15738.2 USD — | 16639.8 USD — | — - | — — |
| NASDAQ-100 Pre Market Indicator QMI | 22773.8 USD — |
+0.32
|
— — | 22743.7 USD — | 22773.8 USD — | — - | — — |
| NASDAQ OMX CRD Global Sustainab QCRD | 1595.1 USD — |
0
|
— — | — — | — — | — - | — — |
| Folksam OMXS60 Cap FMOMXS60CAP | 168.13 SEK 16.41 USD |
+100
|
— — | — — | — — | — - | — — |
| EXBIZ OMX Stockholm Benchmark S OMXSBSHARIA | 1636.08 SEK 159.7 USD |
+100
|
— — | — — | — — | — - | — — |
| ^DRG DRG | 942.99 USD — |
+0.91
|
— — | — — | — — | — - | — — |
| NYSE Composite Index NYA | 20608.23 USD — |
+0.32
|
— — | — — | — — | — - | — — |
| Nasdaq Nordea SmartBeta Momentu NQNDMOT | 1268.11 SEK 123.78 USD |
+0.5
|
— — | — — | — — | — - | — — |
| NASDAQ-100 Ex-Tech Sector NDXX | 5925.15 USD — |
+0.12
|
— — | 5894.28 USD — | 5932.11 USD — | — - | — — |
| Nasdaq-100 ESG JPY Index NDXESG07 | 2241.74 JPY 15.13 USD |
+0.43
|
— — | 2229.49 JPY 15.05 USD | 2247.82 JPY 15.17 USD | — - | — — |
| NASDAQ-100 Notional Net Total R XNDXNNR | 26511.22 USD — |
+0.72
|
— — | 26359.03 USD — | 26569.68 USD — | — - | — — |
| VINX30 VINX30 | — — |
0
|
— — | — — | — — | — - | — — |
| NASDAQ Biotechnology NBI | 4440.47 USD — |
+2.71
|
— — | 4354.94 USD — | 4441.55 USD — | — - | — — |
- {{ link.label }} {{link}}